• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Bright Green Corporation filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    3/21/25 9:15:14 AM ET
    $BGXX
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $BGXX alert in real time by email
    false 0001886799 0001886799 2025-03-17 2025-03-17 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

     

    FORM 8-K

     

    CURRENT REPORT

    PURSUANT TO SECTION 13 OR 15(d) OF

    THE SECURITIES EXCHANGE ACT OF 1934

     

    Date of Report (Date of earliest event reported): March 17, 2025

     

    Bright Green Corporation

    (Exact name of registrant as specified in its charter)

     

    Delaware   001-41395   83-4600841

    (State or other jurisdiction

    of incorporation)

     

    (Commission

    File Number)

     

    (I.R.S. Employer

    Identification No.)

     

    401 E Las Olas Blvd #1400

    Fort Lauderdale, Florida

      33301
    (Address of principal executive offices)   (Zip Code)

     

    Registrant’s telephone number, including area code: (833) 658-1799

     

     

     

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading symbol(s)   Name of each exchange on which registered
    Common Stock, par value $0.0001 per share   BGXX   Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 7.01 Regulation FD Disclosure.

     

    Plan and Disclosure Statement

     

    As previously disclosed, on February 22, 2025, Bright Green Corporation (the “Company”) filed a voluntary petition (the “Chapter 11 Case”) in the United States Bankruptcy Court for the District of New Mexico (the “Bankruptcy Court”) seeking relief under Chapter 11 of Title 11 of the United States Code (the “Bankruptcy Code”). The Company continues to operate its business and manage its properties as a “debtor-in-possession” under the jurisdiction of the Bankruptcy Court and in accordance with the applicable provisions of the Bankruptcy Code and orders of the Bankruptcy Court.

     

    On March 17, 2025, the Company filed a proposed Chapter 11 Plan of Reorganization of the Company (the “Proposed Plan”) and a related proposed form of Disclosure Statement (the “Proposed Disclosure Statement”) with the Bankruptcy Court. The Proposed Plan and the related Proposed Disclosure Statement describe, among other things, the Proposed Plan; the restructuring of the Company (the “Restructuring”); the events leading to the Chapter 11 Case; certain events that have occurred or are anticipated to occur during the Chapter 11 Case, including the anticipated solicitation of votes to approve the Proposed Plan from certain of the Company’s creditors; and certain other aspects of the Restructuring.

     

    Although the Debtors intend to pursue the Restructuring in accordance with the terms set forth in the Proposed Plan, there can be no assurance that the Proposed Plan will be approved by the Bankruptcy Court or that the Company will be successful in consummating the Restructuring or any other similar transaction on the terms set forth in the Proposed Plan, on different terms or at all. Bankruptcy law does not permit solicitation of acceptances of a proposed Chapter 11 plan of reorganization until the Bankruptcy Court approves a disclosure statement relating to the Proposed Plan. Accordingly, neither the Company’s filing of the Proposed Plan and Proposed Disclosure Statement, nor this Current Report on Form 8-K, is a solicitation of votes to accept or reject the Proposed Plan. Any such solicitation will be made pursuant to and in accordance with applicable law, including orders of the Bankruptcy Court. The Proposed Disclosure Statement is being submitted to the Bankruptcy Court for approval but has not been approved by the Bankruptcy Court to date.

     

    Information contained in the Proposed Plan and the Proposed Disclosure Statement is subject to change, whether as a result of amendments or supplements to the Proposed Plan or Proposed Disclosure Statement, third-party actions, or otherwise, and should not be relied upon by any party. Such amendments and supplements may be filed with the Bankruptcy Court without the filing of an accompanying Current Report on Form 8-K.

     

    Copies of the Proposed Plan and the Proposed Disclosure Statement are attached as Exhibit 99.1 and 99.2, respectively, to this Current Report on Form 8-K. The foregoing description of the Proposed Plan and Proposed Disclosure Statement is a summary only and is qualified in its entirety by reference to the full text of the Proposed Plan and the Proposed Disclosure Statement.

     

    On March 21, 2025, the Company issued a press release concerning the Proposed Plan and Proposed Disclosure Statement, a copy of which is furnished herewith as Exhibit 99.3.

     

    The information furnished pursuant to this Item 7.01, including Exhibits 99.1 through 99.3, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities under that Section, and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act.

     

    Cautionary Information Regarding Trading in the Company’s Securities.

     

    The Company’s securityholders are cautioned that trading in the Company’s securities during the pendency of the Chapter 11 Case is highly speculative and poses substantial risks. Trading prices for the Company’s securities may bear little or no relationship to the actual recovery, if any, by holders thereof in the Company’s Chapter 11 Case, and the effectiveness of the Prepackaged Plan is subject to numerous conditions, including approval by the Bankruptcy Court.

     

    2

     

     

    Cautionary Note Regarding Forward-Looking Statements

     

    This Current Report on Form 8-K contains forward-looking statements, which are based on the Company’s current expectations, estimates, and projections about the businesses and prospects of the Company and its subsidiaries, as well as management’s beliefs, and certain assumptions made by management. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “may,” “should,” “will” and variations of these words are intended to identify forward-looking statements. Such statements speak only as of the date hereof and are subject to change. The Company undertakes no obligation to revise or update publicly any forward-looking statements for any reason. These statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict.

     

    Forward-looking statements discuss, among other matters: the Company’s strategy; risks and uncertainties associated with the Chapter 11 Case; the negative impacts on the Company’s businesses as a result of filing for and operating under Chapter 11 protection; the time, terms and ability to confirm a Chapter 11 plan of reorganization for the Company’s businesses; the adequacy of the capital resources of the Company’s businesses and the difficulty in forecasting the liquidity requirements of the operations of its businesses; the unpredictability of the Company’s financial results while in Chapter 11 proceedings; the Company’s ability to discharge claims in Chapter 11 proceedings; negotiations with its trade creditors and other significant creditors; risks and uncertainties with performing under the terms of the Restructuring Support Agreement and any other arrangement with creditors while in Chapter 11 proceedings; the Company’s ability to conduct business as usual in the United States and worldwide; the Company’s ability to continue to serve customers, suppliers and other business partners at the high level of service and performance they have come to expect from the Company; the Company’s ability to continue to pay suppliers and vendors; the ability to control costs during the Chapter 11 Case; the risk that the Company’s Chapter 11 Case may be converted to a case under Chapter 7 of the Bankruptcy Code; the Company’s ability to secure operating capital; the Company’s ability to take advantage of opportunities to acquire assets with upside potential; the Company’s ability to execute on its strategic plan to pursue, evaluate and close a restructuring pursuant to the Prepackaged Plan or another plan of reorganization; the Company’s long-term outlook; the Company’s preparation for future market conditions; and any statements or assumptions underlying any of the foregoing. Such statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict. Accordingly, actual results could differ materially and adversely from those expressed in any forward-looking statements as a result of various factors.

     

    Important factors that may cause such differences include, but are not limited to, the decisions of the Bankruptcy Court; negotiations with the Company’s creditors and any committee approved by the Bankruptcy Court; the Company’s ability to meet the requirements, and compliance with the terms, including restrictive covenants, of the Restructuring Support Agreement and any other financial arrangement while in Chapter 11 proceedings; changes in the Company’s cash needs as compared to its historical operations or its planned reductions in operating expense; adverse litigation; changes in domestic and international demand for the Company’s products; the Company’s ability to control operating costs and other expenses; that general economic conditions may be worse than expected; that competition may increase significantly; changes in laws or government regulations or policies affecting the Company’s current business operations and, as well as those risks and uncertainties disclosed under the sections entitled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in the Company’s Form10-K for the year ended December 31, 2023 filed with the Securities and Exchange Commission (“SEC”) on April 16, 2024, and similar disclosures in subsequent reports filed with the SEC.

     

    SECTION 9 – Financial Statements and Exhibits

     

    Item 9.01 Financial Statements and Exhibits.

     

    Exhibit No.   Description
    99.1   Chapter 11 Plan of Reorganization of the Company, dated March 17, 2025
    99.2   Disclosure Statement, dated March 17, 2025
    99.3   Press Release, dated March 21, 2025
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

    3

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Bright Green Corporation  
       
    /s/ Lynn Stockwell  
    Lynn Stockwell  
    CEO and Director  
       
    Date: March 21, 2025  

     

    4

    Get the next $BGXX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BGXX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BGXX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Bright Green Corporation (Amendment)

      SC 13D/A - Bright Green Corp (0001886799) (Subject)

      9/6/23 5:19:19 PM ET
      $BGXX
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13D filed by Bright Green Corporation

      SC 13D - Bright Green Corp (0001886799) (Subject)

      6/15/23 4:30:21 PM ET
      $BGXX
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by Bright Green Corporation (Amendment)

      SC 13G/A - Bright Green Corp (0001886799) (Subject)

      6/12/23 5:28:12 PM ET
      $BGXX
      Medicinal Chemicals and Botanical Products
      Health Care

    $BGXX
    Leadership Updates

    Live Leadership Updates

    See more
    • (Updated) U.S. Legal Cannabis Pioneer Bright Green Corporation Appoints Industry Veteran Groovy Singh as New Chief Executive Officer

      Singh's appointment comes in support of the Company's next evolution, which will be focused on investing in top talent, commencement of commercial operations, and investing in clinical research and development of plant based therapies, and expanding into cultivation and manufacturing of other scheduled substances. GRANTS, N.M., Jan. 14, 2024 (GLOBE NEWSWIRE) -- Bright Green Corporation (NASDAQ:BGXX) ("Bright Green" or "the Company"), announced today their appointment of Groovy Singh, a renowned leader and strategist in the cannabis and wellness industries, as Chief Executive Officer. Singh will replace current CEO Seamus McAuley, who is stepping back from the position to address recently

      1/14/24 10:00:00 AM ET
      $BGXX
      Medicinal Chemicals and Botanical Products
      Health Care
    • U.S. Legal Cannabis Pioneer Bright Green Corporation Appoints Industry Veteran Groovy Singh as New Chief Executive Officer

      Singh's appointment comes in support of the Company's next evolution, which will be focused on investing in top talent, commencement of commercial operations, and investing in clinical research and development of plant based therapies, and expanding into cultivation and manufacturing of other scheduled substances. GRANTS, N.M., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Bright Green Corporation (NASDAQ:BGXX) ("Bright Green" or "the Company"), announced today their appointment of Groovy Singh, a renowned leader and strategist in the cannabis and wellness industries, as Chief Executive Officer. Singh will replace current CEO Seamus McAuley, who is stepping back from the position to address recently

      10/3/23 11:11:00 AM ET
      $BGXX
      Medicinal Chemicals and Botanical Products
      Health Care
    • Bright Green Announces First Quarter 2023 Financial Update and Milestone Progress

      Bright Green has achieved several key milestones throughout the Quarter significantly advancing progress against its strategic plan, including a historic DEA Federal Registration and License Approval. Commencement of its fundamental capital raise of $500+ million utilizing the U.S. Citizen & Immigration Services EB-5 program, alongside the recently announced full acquisition of Alterola Biotech, showcases the Company's significant progress against its strategic plan. Company has raised short-term working Capital of $5.26m to commence its operations as it looks to capitalize on its historic DEA Registration in Q2 2023 and beyond. GRANTS, N.M., May 24, 2023 (GLOBE NEWSWIRE) -- Brig

      5/24/23 8:00:00 AM ET
      $BGXX
      Medicinal Chemicals and Botanical Products
      Health Care

    $BGXX
    SEC Filings

    See more

    $BGXX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • SEC Form 25-NSE filed by Bright Green Corporation

      25-NSE - Bright Green Corp (0001886799) (Subject)

      3/21/25 11:19:49 AM ET
      $BGXX
      Medicinal Chemicals and Botanical Products
      Health Care
    • Bright Green Corporation filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Bright Green Corp (0001886799) (Filer)

      3/21/25 9:15:14 AM ET
      $BGXX
      Medicinal Chemicals and Botanical Products
      Health Care
    • Bright Green Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Bankruptcy or Receivership, Financial Statements and Exhibits

      8-K - Bright Green Corp (0001886799) (Filer)

      2/27/25 4:05:24 PM ET
      $BGXX
      Medicinal Chemicals and Botanical Products
      Health Care
    • Bright Green Corporation Announces the next steps for the completion of its restructuring plan

      FORT LAUDERDALE, FLORIDA, March 21, 2025 (GLOBE NEWSWIRE) -- Bright Green Corporation (OTC:BGXX) ("Bright Green" or the "Company") announced that on March 17, 2025, on behalf of the Company, Lynn Stockwell has asked the court to approve the "RSA" Restructuring Security Agreement, Disclosure Statement and Plan. The highlights of the Plan and Disclosure will provide new equity for the company to pay all creditors with approved claims in full, in addition the Company equity shareholders will retain their interests in the Company and are unimpaired with no dilution. Lynn Stockwell, the new Chief Executive Officer and Chairman of the Board of Directors of Bright Green Corporation, is also the

      3/21/25 9:15:00 AM ET
      $BGXX
      Medicinal Chemicals and Botanical Products
      Health Care
    • Bright Green Corporation Announces the completion of its restructuring plan, withdraws from the Cannabis business and sets course on the production of all DEA Scheduled Controlled Substances

      FORT LAUDERDALE, FLORIDA, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Bright Green Corporation (OTC:BGXX) ("Bright Green" or the "Company") announced that on February 24, 2025, on behalf of the Company, Lynn Stockwell has asked the court to approve the "RSA" Restructuring Security Agreement. The highlights of the RSA will provide new equity for the company to pay all creditors with approved claims in full, in addition the Company equity shareholders will retain their interests in the Company and are unimpaired with no dilution. The Company in its restructuring efforts has entered into an agreement with the DEA to immediately withdraw all Cannabis related renewal applications. This agreement will a

      2/24/25 9:15:00 AM ET
      $BGXX
      Medicinal Chemicals and Botanical Products
      Health Care
    • Bright Green Corporation Has Signed Agreement with Majority Shareholder as Plan Sponsor on Prepackaged Plan to Restructure the Company.

      The Company plans to emerge with federal loan guarantees for its 60 new mega farm owner/operators, that collectively will invest $3.5 billion to supply and strengthen the Drugs Made in America supply Chain. FORT LAUDERDALE, FLORIDA, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Bright Green Corporation (OTC:BGXX) ("Bright Green" or the "Company") announced that on January 21, 2025, it has entered into a Restructuring Support Agreement (the "RSA") with Lynn Stockwell, a major shareholder of the Company (the "Plan Sponsor") to restructure the Company. To implement the terms of the RSA, the Company will file, and the Plan Sponsor will support the Company's Prepackaged Plan of Reorganization Under Chapte

      1/27/25 8:17:00 PM ET
      $BGXX
      Medicinal Chemicals and Botanical Products
      Health Care

    $BGXX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Elmasri Saleem sold $4,951 worth of shares (25,942 units at $0.19), decreasing direct ownership by 2% to 1,103,476 units (SEC Form 4)

      4 - Bright Green Corp (0001886799) (Issuer)

      9/11/24 4:05:11 PM ET
      $BGXX
      Medicinal Chemicals and Botanical Products
      Health Care
    • Chief Financial Officer Elmasri Saleem sold $14,313 worth of shares (71,809 units at $0.20), decreasing direct ownership by 6% to 1,129,418 units (SEC Form 4)

      4 - Bright Green Corp (0001886799) (Issuer)

      9/10/24 4:05:08 PM ET
      $BGXX
      Medicinal Chemicals and Botanical Products
      Health Care
    • Amendment: Chief Executive Officer Singh Gurvinder was granted 5,500,000 shares (SEC Form 4)

      4/A - Bright Green Corp (0001886799) (Issuer)

      9/9/24 4:05:32 PM ET
      $BGXX
      Medicinal Chemicals and Botanical Products
      Health Care